Bluebird bio to sell to investment funds after struggling to make money from gene therapies
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out of time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
